ProQR Therapeutics (NASDAQ:PRQR) Price Target Raised to $12.00 at HC Wainwright

ProQR Therapeutics (NASDAQ:PRQR) had its price target hoisted by HC Wainwright from $10.00 to $12.00 in a research report sent to investors on Friday,Benzinga reports. The firm currently has a buy rating on the biopharmaceutical company’s stock.

PRQR has been the subject of several other reports. JMP Securities restated a “market outperform” rating and issued a $8.00 price objective on shares of ProQR Therapeutics in a report on Thursday, December 12th. Oppenheimer began coverage on shares of ProQR Therapeutics in a report on Friday, January 10th. They issued an “outperform” rating and a $15.00 price objective for the company. StockNews.com lowered shares of ProQR Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, November 28th. Chardan Capital restated a “buy” rating and issued a $4.00 price objective on shares of ProQR Therapeutics in a report on Friday. Finally, Citigroup upgraded shares of ProQR Therapeutics from a “neutral” rating to a “buy” rating and set a $4.00 price objective for the company in a report on Monday, March 10th. One research analyst has rated the stock with a sell rating, five have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, ProQR Therapeutics has an average rating of “Moderate Buy” and an average target price of $9.50.

ProQR Therapeutics Trading Down 2.9 %

ProQR Therapeutics stock opened at $1.69 on Friday. The firm has a 50-day moving average of $2.25 and a 200-day moving average of $2.61. The firm has a market cap of $138.04 million, a P/E ratio of -5.28 and a beta of 0.24. ProQR Therapeutics has a 1-year low of $1.61 and a 1-year high of $4.62.

Hedge Funds Weigh In On ProQR Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the business. BNP Paribas Financial Markets increased its stake in shares of ProQR Therapeutics by 14.2% during the third quarter. BNP Paribas Financial Markets now owns 58,801 shares of the biopharmaceutical company’s stock valued at $107,000 after purchasing an additional 7,300 shares in the last quarter. OneDigital Investment Advisors LLC increased its stake in shares of ProQR Therapeutics by 37.0% during the third quarter. OneDigital Investment Advisors LLC now owns 57,550 shares of the biopharmaceutical company’s stock valued at $105,000 after purchasing an additional 15,550 shares in the last quarter. Ballentine Partners LLC bought a new position in shares of ProQR Therapeutics during the fourth quarter valued at approximately $61,000. Altium Capital Management LLC bought a new position in shares of ProQR Therapeutics during the fourth quarter valued at approximately $1,524,000. Finally, Affinity Asset Advisors LLC bought a new position in shares of ProQR Therapeutics during the fourth quarter valued at approximately $7,486,000. Institutional investors own 32.65% of the company’s stock.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).